The US FDA has accepted Wockhardt’s New Drug Application for Zaynich, its first-in-class antibiotic. This marks the ...

For only the second time since launching nearly two years ago, the AMR Action Fund has announced an investment in a fledgling biotech company as it tries to underwrite efforts to develop badly needed ...

LONDON – Twenty-three pharmaceutical companies are joining forces in the AMR Action fund and have raised $1 billion for the clinical development of antibiotic drugs addressing the most resistant ...

A who’s who of Big Pharma companies, including Pfizer, Johnson & Johnson and Merck, has banded together to bolster the development of new antibiotics. The companies announced Thursday the $1 billion ...

Advanz Pharma secured rights to Polypid’s prolonged-release antibiotic candidate D-PLEX100, paying $2.6 million upfront and dangling more than $100 million in milestones to secure the European license ...

GlaxoSmithKline plans to shut down antibiotics production in the U.K. after wrapping up a $500 million product sale to Novartis’ Sandoz. GSK will finish out its supply commitment to Sandoz—a deal that ...

Health experts have rounded on pharma companies as having “endless talk and no action” when it comes to antibiotic R&D, as governments around the world continue to sound alarm bells over a potential ...

Forget COVID-19, monkeypox, and other viruses for the moment and consider another threat troubling infectious disease specialists: common urinary tract infections, or UTIs, that lead to emergency room ...

One approach federal lawmakers have used to jumpstart certain types of drug development has been to offer vouchers to companies that can later be redeemed when seeking approval for yet another ...